Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)

被引：1
|
作者：
Cohn, A. L.
Bekaii-Saab, T.
Bendell, J. C.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
机构：
[1] Rocky Mt Canc Ctr, Denver, CO USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Ingalls Hosp, Harvey, IL USA
[6] Univ Chicago, Harvey, IL USA
[7] C3, Alexandria, VA USA
[8] North Idaho Canc Ctr, Coeur Dalene, ID USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3596
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
    Bendell, Johanna C.
    Beikaii-Saab, Tanios S.
    Cohn, Allen L.
    Hurwitz, Herbert I.
    Kozloff, Mark
    Tezcan, Haluk
    Roach, Nancy
    Mun, Yong
    Fish, Susan
    Flick, E. Dawn
    Dalal, Darshan
    Grothey, Axel
    ONCOLOGIST, 2012, 17 (12): : 1486 - 1495
  • [42] RISK OF SEVERE PULMONARY HEMORRHAGE (SPH) ASSOCIATED WITH DEVELOPMENT OF CAVITATION WHILE ON BEVACIZUMAB (BV) THERAPY IN PATIENTS (PTS) WITH NON SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM ARIES, A BV TREATMENT OBSERVATIONAL COHORT STUDY (OCS)
    Spigel, D. R.
    Brahmer, J. R.
    Fischbach, N. A.
    Kumar, P.
    Kosty, M.
    Wozniak, A. J.
    Teng, S. L.
    Flick, E. D.
    Sing, A. P.
    Lynch, T. J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S84 - S84
  • [43] Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
    Grothey, Axel
    Flick, E. Dawn
    Cohn, Allen L.
    Bekaii-Saab, Tanios S.
    Bendell, Johanna C.
    Kozloff, Mark
    Roach, Nancy
    Mun, Yong
    Fish, Susan
    Hurwitz, Herbert I.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) : 726 - 734
  • [44] Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk.
    Kabbinavar, F.
    Zurlo, A.
    Irl, C.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 155S - 155S
  • [45] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
    Grothey, Axel
    Sugrue, Mary M.
    Purdie, David M.
    Dong, Wei
    Sargent, Daniel
    Hedrick, Eric
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5326 - 5334
  • [46] EGFL7 polymorphism to predict tumor response in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI and bevacizumab (BV)
    Li, Joseph Ethan
    Zhang, Wu
    Loupakis, Fotios
    Yang, Dongyun
    Wakatsuki, Takeru
    Ning, Yan
    Stintzing, Sebastian
    El-Khoueiry, Rita Elie
    Volz, Nico Benjamin
    Marmorino, Federica
    Schirripa, Marta
    Salvatore, Lisa
    Antoniotti, Carlotta
    Cremolini, Chiara
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
    Kozloff, Mark
    Yood, Marianne Ulcickas
    Berlin, Jordan
    Flynn, Patrick J.
    Kabbinavar, Fairooz F.
    Purdie, David M.
    Ashby, Mark A.
    Dong, Wei
    Sugrue, Mary M.
    Grothey, Axel
    ONCOLOGIST, 2009, 14 (09): : 862 - 870
  • [48] CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY
    Bendell, J.
    Cohn, A.
    Mun, Y.
    Fish, S.
    Sommer, N.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [49] Preliminary safety and effectiveness of bevacizumab- (BV) based treatment in subpopulations of patients with non-small cell lung cancer (NSCLC) from the ARIES study: a BV treatment observational cohort study (OCS)
    Fischbach, Neal
    Spigel, David R.
    Brahmer, Julie
    Robles, Robert
    Teng, Siew L.
    Wang, Lisa
    Sing, Amy P.
    Lynch, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S360 - S360
  • [50] Use of Bevacizumab (BV) After Induction Therapy is Associated With Survival Benefit in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS)
    Kosty, M. P.
    Brahmer, J. R.
    Jahanzeb, M.
    Kumar, P.
    Robles, R.
    Wozniak, A. J.
    Leon, L.
    Flick, E. D.
    Dalal, D.
    Lynch, T. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S598 - S598
12345